Sun Pharmaceutical Industries Ltd. News and Updates

Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Sun Pharmaceutical Industries Ltd. from all sources in a single place.

Load latest

Sun Pharmaceutical Industries Ltd.

06 Aug 2020

1622.00

-0.87%

SUN PHARMA

Hold: Sun Pharmaceutical Industr...

Recommendation Target

Geojit BNP Paribas

Weak US business impacts Q1; Outlook cautious Sun Pharma is India's top drug maker and world's fifth largest specialty generic pharmaceutical company. The company develops, manufactures, and markets branded and generic formulations and active pharmaceutical...

Sun Pharmaceutical Industries Ltd.'s price crossed below 50Day SMA today

Sun Pharmaceutical Industries Ltd.

04 Aug 2020

1622.00

-0.87%

Coronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet

Moneycontrol

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.

Sun Pharmaceutical Industries Ltd. is trading below its 50 day SMA of 1627.2

Sun Pharma launches its version of Covid-19 drug Favipiravir

Business Line | 04 Aug 2020 1 more

Sun Pharmaceutical Industries Ltd.

03 Aug 2020

1622.00

-0.87%

Ideas For Profit | Will Sun Pharma's steady India business, US speciality portfolio help it do well in FY21?

Moneycontrol

In this edition of Ideas For Profit, Moneycontrol's Sakshi Batra decodes Sun Pharma Q1 results and suggests what strategy investors could adopt now.

Sun Pharmaceutical Industries Ltd.'s price crossed below 50Day SMA today

Sun Pharma's steady India business and US specialty portfolio should help it do well in FY22

Moneycontrol | 03 Aug 2020, 09:47AM

Sun Pharmaceutical Industries Ltd.

03 Aug 2020

1622.00

-0.87%

Hold Sun Pharmaceutical Industries; target of Rs 479: Prabhudas Lilladher

Moneycontrol

Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 479 in its research report dated July 31, 2020.

Sun Pharmaceutical Industries Ltd. is trading above its 30 day SMA of 1610.0

Top buy and sell ideas by Ashwani Gujral, Sudarshan Sukhani, Mitesh Thakkar for short term

Moneycontrol | 03 Aug 2020, 08:48AM

Sun Pharmaceutical Industries Ltd.

03 Aug 2020, 12:00AM

1622.00

-0.87%

Sun Pharmaceutical Industries Ltd

Sell: Sun Pharmaceutical Industr...

Recommendation Target

Karvy

Outlook & Valuation: We downgrade our revenues by 4%/2% to Rs 348 Bn/Rs 385Bn for FY21E/FY22E on account of downgrade in Domestic formulations, US/Taro and other businesses.

Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr

Sun Pharmaceutical Industries Ltd.

02 Aug 2020, 12:00AM

1622.00

-0.87%

Q1FY21 Result Update - Specialty, Taro to remain weak; Lower overhead likely to be unsustainable - Downgrade to 'Reduce'

Sell: Sun Pharmaceutical Industr...

Recommendation

Prabhudas Lilladhar

Net loss of Rs16.5bn due to Taro DOJ settlement and provision SUNP 1QFY21 revenue were lower than our estimate because of US specialty and Taro sales while adj. EBITDA margin positively surprised at 23.1% (PLe :20.4%) due to 1) lower R&D; spend (5.6% of sales v/s 6.4% QoQ) and 2) lower SGA costs led by travel restriction on employees and lower marketing...

Sun Pharmaceutical Industries Ltd.'s price crossed below 30Day SMA today

Sun Pharmaceutical Industries Ltd.

02 Aug 2020, 12:00AM

1622.00

-0.87%

Sun Pharma

Buy: Sun Pharmaceutical Industr...

Target

ICICI Securities Limited

Revenues de-grew 9.4% YoY to | 7585 crore (I-direct estimate: | 7948 crore) mainly due to 27.5% YoY decline in US formulations to | 2136 crore due to high base and continued pressure on dermatology segment (Taro included). India business grew 3.2% YoY to | 2388 crore whereas Emerging Markets business de-grew 2.4% YoY to | 1316 crore. RoW markets business also degrew 11.1% YoY to | 1030 crore. EBITDA margins expanded 47 bps YoY, 765 bps QoQ to 24.3% (I-direct estimate: 17.0%) despite higher employee expenses mainly due to lower other expenditure and better gross margins. EBITDA de-grew 7.6% YoY to | 1844 crore (I-direct estimate: | 1351 crore)....

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

01 Aug 2020

1622.00

-0.87%

Sun Pharma (REDUCE): Mixed Q1; margin beat unlikely to sustain REDUCE

Sell: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Sun Pharma (SUNP) posted an 11% EBITDA beat but an 8% miss on sales.

Sun Pharmaceutical Industries Ltd. is trading below its 50 day SMA of 1627.2

Sun Pharmaceutical Industries Ltd.

01 Aug 2020

1622.00

-0.87%

COVID-19 impacts sales in EMs/US/ROW

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Despite the adverse impact on off-take of its Specialty portfolio due to COVID, SUNPs market share remained intact and gradual recovery is expected over the near-to-medium term. Maintain SUNPs 1QFY21 sales were down 10% YoY to INR75.7b (v/s est. Accordingly, we have raised our price target to INR635 (from INR525 earlier) on We believe SUNPs RoE is at a trough and would improve with 19% earnings CAGR over FY20-22E, led by improving traction in the Specialty portfolio, enhanced MR efforts in DF, and better operating leverage. Considering that market share remains intact, SUNP is continuing its efforts to build more traction in its Specialty portfolio. We expect US sales to show moderate growth SUNP delivered 3% YoY growth in 1QFY21 despite challenging market conditions on account of COVID. We expect 9% sales CAGR over FY20-22E in this segment, led by increased traction in DF outperformance (v/s industry) coupled with recovery from COVID related disruptions and gradual improvement in the Specialty portfolio segment.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Sun Pharmaceutical Industries Ltd.

31 Jul 2020

1622.00

-0.87%

Sun Pharma posts 1,656 cr Q1 loss on legal woes in US

livemint

The loss was caused by a one-time settlement in a price-fixing case involving Taro.Taro, a Sun Pharma subsidiary, reported settlements and loss contingencies of $478.9 million